Our Stellar Team

Who is California Cannabinoids?

California Cannabinoids™ is a California Corporation formed in 2017, to provide the cannabis industry and consumers access to tetrahydrocannabivarin (THCV), a rare but popular cannabinoid known for its unique properties.

California Cannabinoids™ is the exclusive provider of Doug’s Varin™, known around the world to have one of the highest concentrations of THCV. The first major product offerings by the company will roll out in the fourth quarter of 2018, with a larger roll-out of premium product in-early 2019.

This high THCV line of products was founded in 2013, by Doug, whose wife was suffering from Multiple Sclerosis. A botanist and serial believer in holistic and alternative therapies, Doug set out to find a strain of cannabis that would help his wife cope with her illness. In 2012, Doug's wife passed on, but he relentlessly continued the search - after 40,000 iterations, Doug's Varin™ was discovered.

After its discovery by Doug, many have attempted to produce a similar cannabinoid profile to harness the power of THCV, but no one has come close. In 2012, California Cannabinoids™ industry expert, serial entrepreneur, co-founder and CEO David Lampach met Doug, discussed the significance of the discovery and the two began a lasting personal and professional relationship. Today, California Cannabinoids™ is the exclusive producer and parent company of Doug’s Varin™and the company continues his mission with his blessing to bring THCV to the masses for personal health.

All of the Doug’s Varin™ products are grown under full sun in Northern California and are tested for safety and potency under California BCC regulatory standards. In addition to creating its own exclusive retail products, the company licenses Doug’s Varin™ to stable, long term manufacturers who are looking to include Doug’s Varin™ in their product offerings.

Who Is On The Team?

David Lampach, CEO

David has been at the forefront of the cannabis industry for over 15 years. He was CEO and co-founder of Steep Hill Labs from 2007 - 2015. Under his direction, Steep Hill grew from its founding in 2008 as the first cannabis testing company in the United States to a major national cannabis science brand, with locations in many U.S. cannabis states. He developed QuantaCann, the first remote instant potency analyzer for cannabis. He has worked in both official and unofficial capacities for several state and foreign governments on the subject of cannabis quality assurance and regulation. He has been a cannabis cultivator for over 15 years.

Sheila Hoyt, CBDO

In 2011, Sheila Hoyt began her career in the cannabis industry as the co-founder of the groundbreaking digital tabletop vaporizer, the Herbalizer in San Diego, CA. Serving as Director of Sales and Marketing since the company’s inception, she networked with other industry leaders working to build awareness and education for medical cannabis use. Working directly with engineering to help shape the technology behind a company’s products, Hoyt also creates a go-to-market strategy, develops strategic business partnerships, marketing management, established affiliate programs, and hired and trained and managed customer service teams. Hoyt brings new business creation and strategic planning, market segmentation, product management and roadmap development, financial modeling, public relations, business development to the endeavor. Other companies she has lead in sales development and marketing include the Anthony Robbins Companies (Tony Robbins), and Avon, LLC.

christian yavorsky, Ph.D.

Dr. Christian Yavorsky has extensive experience in the pharmaceutical industry and has been involved in over 60 Phase I, II and III clinical trials in psychiatry and neurology. Dr. Yavorsky pioneered risk-based approaches to addressing data quality in psychiatric drug trials and continues to be involved in the investigation of new compounds to improve patient lives. His current projects include the evaluation of NMDA-receptor antagonist treatment for treatment resistant depression and THC-V, a neutral CB1 antagonist, as a novel treatment for a hard to treat neurological disorder.